HCW Biologics is trading 8.92% up at $2.32 in after-hours trading, with no major August 18 company-specific announcement clearly explaining the rebound.

  • It closed at $2.13 on August 18, 2026.
  • Its August 14 second-quarter report highlighted continued clinical progress but severe liquidity pressure, including $741,324 in cash as of June 30.
  • Broader markets moved lower, so macro sentiment does not directly explain the gain.